Evidence map›Paper›PMID 40326623›Full record

ArticleNanomedicine (London, England)2025

Drug-loaded nanoparticles induce immunogenic cell death and efficiently target cells from glioblastoma patients.

Ada Tushe, Elena Marinelli, Beatrice Musca, Annavera Ventura, Sara Zumerle, Olga Slukinova, Giulia Zampardi, Francesco Volpin, Camilla Bonaudo, Alessandro Della Puppa and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ada TusheVeneto Institute of Oncology IOV, IRCCS, Padua, Italy.ORCID 0009-0002-0687-7834
Elena MarinelliVeneto Institute of Oncology IOV, IRCCS, Padua, Italy.ORCID 0009-0005-8663-0736
Beatrice MuscaVeneto Institute of Oncology IOV, IRCCS, Padua, Italy.
Annavera VenturaVeneto Institute of Oncology IOV, IRCCS, Padua, Italy.
Sara ZumerleVeneto Institute of Oncology IOV, IRCCS, Padua, Italy.
Olga SlukinovaDepartment of Surgery, Oncology and Gastroneterology, University of Padua, Padua, Italy.
Giulia ZampardiVeneto Institute of Oncology IOV, IRCCS, Padua, Italy.
Francesco VolpinDivision of Neurosurgery, University Hospital of Padova, Padova, Italy.
Camilla BonaudoNeurosurgery, Department of NEUROFARBA, University of Florence, University Hospital of Careggi, Florence, Italy.
Alessandro Della PuppaNeurosurgery, Department of NEUROFARBA, University of Florence, University Hospital of Careggi, Florence, Italy.
Mathieu RepellinLaboratoire D'Automatique, de Génie des Procédés et de Génie Pharmaceutique, LAGEPP UMR 5007, University Lyon 1, CNRS, Lyon, France.ORCID 0000-0003-0613-3667
Giulia GuerrieroLaboratoire D'Automatique, de Génie des Procédés et de Génie Pharmaceutique, LAGEPP UMR 5007, University Lyon 1, CNRS, Lyon, France.
Giovanna LolloLaboratoire D'Automatique, de Génie des Procédés et de Génie Pharmaceutique, LAGEPP UMR 5007, University Lyon 1, CNRS, Lyon, France.
Susanna MandruzzatoVeneto Institute of Oncology IOV, IRCCS, Padua, Italy.ORCID 0000-0002-0707-995X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimGlioblastoma multiforme (GBM) is characterized by a highly immunosuppressive tumor microenvironment (TME), posing significant challenges for efficient therapy's outcomes. Nanomedicine combined with immunotherapy holds the potential to modulate the TME and reactivate immune responses. This study proposes a polymeric nanosystem (NPs) encapsulating diaminocyclohexane-platinum II (DACHPt), an oxaliplatin derivative, to induce immunogenic cell death (ICD) in GBM cells. MATERIALS &

methodsAn ionic-gelation technique was employed to generate polymeric nanoparticles (NPs) with an approximate size of 200 nm. NPs internalization was analyzed in GBM cell lines,

resultsNPs were efficiently incorporated by myeloid and tumor cells, but not by lymphocytes. DACHPt-loaded NPs demonstrated enhanced cytotoxicity compared to free drug, with increased ATP and HMGB1 release from GBM cells, confirming ICD induction.

conclusionsOur findings suggest that DACHPt-loaded NPs represent a promising therapeutic strategy capable of targeting both tumor cells and tumor-promoting immune cells while inducing ICD.

Indexed as

Antineoplastic AgentsBrain NeoplasmsGlioblastomaImmunogenic Cell DeathNanoparticlesOxaliplatinAdenosine TriphosphateCell Line, TumorHMGB1 ProteinHumansTumor MicroenvironmentAdenosine TriphosphateAntineoplastic AgentsHMGB1 ProteinHMGB1 protein, humanOxaliplatindamage-associated molecular patternsdiaminocyclohexane-platinum II (DACHPt)glioblastomaImmunogenic cell deathoxaliplatinpolymeric nanoparticlestumor microenvironmentU87MG

Identifiers

PMID40326623
PMCPMC12140489

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.